COMMUNIQUÉS West-GlobeNewswire

-
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
07/02/2024 -
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
07/02/2024 -
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy
07/02/2024 -
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
07/02/2024 -
Stryker declares a $0.80 per share quarterly dividend
07/02/2024 -
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
07/02/2024 -
Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07/02/2024 -
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
07/02/2024 -
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
07/02/2024 -
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
07/02/2024 -
New Survey Highlights Dire State of Nursing in 2024, Finds Optimism from Nurses Still in Profession
07/02/2024 -
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
07/02/2024 -
Evaxion annonce la clôture de son offre publique à 15 millions de dollars
07/02/2024 -
Des chercheurs de KFSH&RC et de KAUST découvrent le gène responsable de la reproduction de la souche de paludisme la plus dangereuse qui soit
07/02/2024 -
VALNEVA: Declaration of shares and voting rights - January 31, 2024
07/02/2024 -
VALNEVA : Déclaration d’actions et de droits de vote - 31 janvier 2024
07/02/2024 -
119,021 Orion Corporation A shares converted into B shares
07/02/2024 -
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
07/02/2024 -
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
07/02/2024
Pages